Evaluation of RASGRP1/APTX ratio treatment specificity: characteristics of patients receiving (phase 2) and not receiving (specificity) tipifarnib-based induction therapy for newly diagnosed AML
| . | Phase 2 (n = 40) . | Specificity (n = 41) . |
|---|---|---|
| Sex (male/female) | 21/19 | 19/22 |
| Median age, y (range) | 77 (70-90) | 58 (21-71) |
| Therapy | T + E | Ara-C, anthracycline, and third agent (flavopiridol or etoposide) |
| Cytogenetics, no. (%) | ||
| Favorable | 0 | 5 (10) |
| Normal | 12 (30) | 15 (37) |
| Intermediate | 2 (5) | 4 (10) |
| Adverse | 26 (65) | 17 (41) |
| FLT3-ITD, no. (%)* | 0 | 9 (22) |
| Response, no. (%) | ||
| CR | 11 (28) | 25 (61) |
| PR/HI | 9 (22) | 0 |
| Overall | 20 (50) | 25 (61) |
| . | Phase 2 (n = 40) . | Specificity (n = 41) . |
|---|---|---|
| Sex (male/female) | 21/19 | 19/22 |
| Median age, y (range) | 77 (70-90) | 58 (21-71) |
| Therapy | T + E | Ara-C, anthracycline, and third agent (flavopiridol or etoposide) |
| Cytogenetics, no. (%) | ||
| Favorable | 0 | 5 (10) |
| Normal | 12 (30) | 15 (37) |
| Intermediate | 2 (5) | 4 (10) |
| Adverse | 26 (65) | 17 (41) |
| FLT3-ITD, no. (%)* | 0 | 9 (22) |
| Response, no. (%) | ||
| CR | 11 (28) | 25 (61) |
| PR/HI | 9 (22) | 0 |
| Overall | 20 (50) | 25 (61) |
All FLT3-ITD+ patients had normal cytogenetics.